Sign in
WithdrawnPhase 3

A Phase III Study to Evaluate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy in Patients With Advanced Cervical Cancer

Key facts

Who runs it
Shanghai Henlius Biotech
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Withdrawn
Phase
Phase 3
Started
30 Sept 2022
Ended
30 Oct 2024
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • HLX10
  • Paclitaxel
  • Cisplatin
  • Carboplatin
  • Placebo to HLX10
Record updated
5 May 2022
Why it stopped
The sponsor terminated the trial.

Who can take part

Age
18 years to 75 years
Sex
Women only
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Has persistent, recurrent, or metastatic squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix which has not been treated with systemic chemotherapy and is not amenable to curative treatment (such as with surgery and/or radiation)
  • CPS≥1
  • Has measurable disease per RECIST 1.1 as assessed by IRRC
  • Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 within 14 days prior to randomization
  • Has adequate organ function

Who cannot take part

  • Has received prior therapy with an anti-PD-1, anti-PD-L1 or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g. CTLA-4)
  • Has a known additional malignancy that is progressing or has required active treatment within the past 2 years
  • Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis
  • Has an active infection requiring systemic therapy
  • Has a known history of human immunodeficiency virus (HIV) infection
  • Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The purpose of this study is to assess the efficacy and safety of HLX10(Recombinant Anti-PD-1 Humanized Monoclonal Antibody Injection) plus chemotherapy compared to the efficacy and safety of placebo plus chemotherapy in the treatment of adult women with persistent, recurrent, or metastatic cervical cancer. Chemotherapy regimens include: paclitaxel plus cisplatin and paclitaxel plus carboplatin.

Read full original descriptionShow less

The primary study hypotheses are that the combination of HLX10 plus chemotherapy is superior to placebo plus chemotherapy with respect to: 1) Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST 1.1) as assessed by the IRRC or, 2) Overall Survival (OS).

The 2 groups in the trial

  • HLX10Treatment being tested

    HLX10 + chemotherapy

    Treatment: HLX10, Paclitaxel, Cisplatin, and Carboplatin

  • PlaceboPlacebo, for comparison

    Placebo + chemotherapy

    Treatment: Paclitaxel, Cisplatin, Carboplatin, and Placebo to HLX10

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of First-Line Treatment With HLX10 (Recombinant Anti-PD-1 Humanized Monoclonal Antibody Injection) + Chemotherapy (Carboplatin/Cisplatin and Paclitaxel) vs Chemotherapy (Carboplatin/Cisplatin and Paclitaxel)in Patients With Advanced Cervical Cancer
Record updated
5 May 2022